CN101938904A - 用a2ar激动剂鞘内治疗神经性疼痛 - Google Patents

用a2ar激动剂鞘内治疗神经性疼痛 Download PDF

Info

Publication number
CN101938904A
CN101938904A CN2009801042314A CN200980104231A CN101938904A CN 101938904 A CN101938904 A CN 101938904A CN 2009801042314 A CN2009801042314 A CN 2009801042314A CN 200980104231 A CN200980104231 A CN 200980104231A CN 101938904 A CN101938904 A CN 101938904A
Authority
CN
China
Prior art keywords
alkylene
alkyl
aryl
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801042314A
Other languages
English (en)
Chinese (zh)
Inventor
L·沃特金斯
L·洛拉姆
M·哈钦森
R·汤普森
A·博格莱霍尔
F·施米特曼
J·里格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PGxHealth LLC
Original Assignee
PGxHealth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PGxHealth LLC filed Critical PGxHealth LLC
Publication of CN101938904A publication Critical patent/CN101938904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN2009801042314A 2008-01-09 2009-01-09 用a2ar激动剂鞘内治疗神经性疼痛 Pending CN101938904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1991208P 2008-01-09 2008-01-09
US61/019,912 2008-01-09
PCT/US2009/030565 WO2009089425A1 (en) 2008-01-09 2009-01-09 Intrathecal treatment of neuropathic pain with a2ar agonists

Publications (1)

Publication Number Publication Date
CN101938904A true CN101938904A (zh) 2011-01-05

Family

ID=40851205

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801042314A Pending CN101938904A (zh) 2008-01-09 2009-01-09 用a2ar激动剂鞘内治疗神经性疼痛

Country Status (10)

Country Link
US (1) US20090181920A1 (https=)
EP (1) EP2240020A4 (https=)
JP (1) JP2011509305A (https=)
CN (1) CN101938904A (https=)
AU (1) AU2009204084A1 (https=)
BR (1) BRPI0907248A2 (https=)
CA (1) CA2711495A1 (https=)
EA (1) EA201001135A1 (https=)
IL (1) IL206801A0 (https=)
WO (1) WO2009089425A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363757A (zh) * 2012-02-11 2015-02-18 中央研究院 治疗疼痛的方法及组合物

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011143442A1 (en) * 2010-05-12 2011-11-17 Trovis Pharmaceuticals, Llc. A method of treating multiple sclerosis with adenosine receptor agonists
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US20130324461A1 (en) * 2010-08-26 2013-12-05 Michail V. Sitkovsky Methods and compositions for preventing or treating obesity
RU2013114767A (ru) * 2010-09-29 2014-11-10 СК Биофармасьютикалз Ко., Лтд. Новые производные метилциклогексана и его применение
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
JP2016517426A (ja) 2013-03-15 2016-06-16 エピザイム，インコーポレイティド 置換プリン化合物の合成方法
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946732A (zh) * 2004-03-05 2007-04-11 剑桥生物工艺有限公司 腺苷受体激动剂
CN101068825A (zh) * 2004-08-02 2007-11-07 弗吉尼亚大学专利基金会 具有a2a激动剂活性的具有修饰的5＇－核糖基团的2－丙炔基腺苷类似物
WO2007136817A2 (en) * 2006-05-18 2007-11-29 Adenosine Therapeutics, Llc Substituted aryl piperidinylalkynyladenosines as a2ar agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20080221060A1 (en) * 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946732A (zh) * 2004-03-05 2007-04-11 剑桥生物工艺有限公司 腺苷受体激动剂
CN101068825A (zh) * 2004-08-02 2007-11-07 弗吉尼亚大学专利基金会 具有a2a激动剂活性的具有修饰的5＇－核糖基团的2－丙炔基腺苷类似物
WO2007136817A2 (en) * 2006-05-18 2007-11-29 Adenosine Therapeutics, Llc Substituted aryl piperidinylalkynyladenosines as a2ar agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAIL W. SULLIVAN ET AL.: "A2A Adenosine Receptor Activation Improves Survival in Mouse Models of Endotoxemia and Sepsis", 《THE JOURNAL OF INFECTIOUS DISEASES》 *
PAULINE L. MARTIN ET AL.: "Pharmacology of 2-Cyclohexylmethylidenehydrazinoadenosine (WRC-0470), a Novel, Short-Acting Adenosine A2A Receptor Agonist That Produces Selective Coronary Vasodilation", 《DRUG DEVELOPMENT RESEARCH》 *
YOUN-WOO LEE ET AL.: "Pharmacology of the Spinal Adenosine Receptor Which Mediates the Antiallodynic Action of Intrathecal Adenosine Agonists", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363757A (zh) * 2012-02-11 2015-02-18 中央研究院 治疗疼痛的方法及组合物
CN104363757B (zh) * 2012-02-11 2017-05-24 中央研究院 治疗疼痛的方法及组合物
CN107252433A (zh) * 2012-02-11 2017-10-17 中央研究院 治疗疼痛的方法及组合物

Also Published As

Publication number Publication date
WO2009089425A1 (en) 2009-07-16
US20090181920A1 (en) 2009-07-16
BRPI0907248A2 (pt) 2019-02-26
JP2011509305A (ja) 2011-03-24
CA2711495A1 (en) 2009-07-16
EP2240020A1 (en) 2010-10-20
EA201001135A1 (ru) 2011-02-28
IL206801A0 (en) 2010-12-30
AU2009204084A1 (en) 2009-07-16
EP2240020A4 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
CN101938904A (zh) 用a2ar激动剂鞘内治疗神经性疼痛
CA2384111C (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
DE60318192T2 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
JP2007536241A (ja) 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
US8551972B2 (en) Agonists of A2A adenosine receptors for treating recurrent tumor growth
KR101757940B1 (ko) 인간 안압을 감소시키는 방법
CN1255854A (zh) 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
CN113056272A (zh) 新的喹唑啉egfr抑制剂
JP2009530295A5 (https=)
CN112294965A (zh) Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
JP2025523058A (ja) Ｃｌｂ－ｂ阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置
RS61372B1 (sr) Ligand a3 adenozinskog receptora za primenu u lečenju nagomilavanja ektopične masnoće
HK1152836A (en) Intrathecal treatment of neuropathic pain with a2ar agonists
JP2025523056A (ja) 細胞増殖関連疾患の処置方法におけるｃｂｌ－ｂ阻害剤、ｃｂｌ－ｂ阻害剤を含む組成物
CN111447953A (zh) 用于管理细胞激素释放症候群的a3腺苷受体配体
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
WO2025070603A1 (ja) 血液がんの新規併用療法
JPH0616561A (ja) 抗レトロウイルス剤
HK40054977A (en) Novel quinazoline egfr inhibitors
WO2007000771A2 (en) Fused quinazolinone derivatives and uses thereof
CN114728004A (zh) 用于治疗恶性血液病的组合疗法
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
AU1859399A (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
WO1992009287A1 (en) Combinations of vanilloid compounds and nucleoside antiviral compounds for treatment of herpes infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152836

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1152836

Country of ref document: HK